Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19

SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Santarus, Inc. (Nasdaq: SNTS) announces that a live audio webcast and accompanying slide presentation will be provided for its Analyst Day and Investor Briefing.  

Details of the event are as follows:What:Santarus Analyst Day and Investor BriefingWhen:Today, Wednesday, January 19, 2011 at 4:15 p.m. Eastern (under the Investor Relations link)AGENDA

  • Strategic Overview and 2011 Financial Outlook

  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

  • CYCLOSET® - Clinical/Medical Background

  • Dr. J. Michael Gaziano, Chief, Division of Aging, Brigham & Women’s Hospital,

    Professor of Medicine, Harvard Medical School

  • ULTESA™ (Budesonide MMX®) – Overview and Top-line Phase III Clinical Study Results

  • Dr. Simon P.L. Travis, Consultant Gastroenterologist,

    Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

  • Ulcerative Colitis – Treatment Perspective

  • Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology,

    University of California, San Diego

  • RHUCIN® and Hereditary Angioedema (HAE)

  • Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Allergy and Immunology, University of California, San Diego,

    Research Scientist, San Diego VA Healthcare

  • SAN-300 (anti-VLA-1 antibody)

  • Dr. Mark C. Totoritis, Senior Vice President, Biologics, Santarus, Inc.

  • Wrap-up/Question & Answer Session

  • Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

    How:Live over the Internet – Simply log on to the Investor Relations section of the company's website at www.santarus.comContact:Lippert/Heilshorn & AssociatesNarine Darbinyan310-691-7100About SantarusSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.  The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.  

    Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs:  ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea.  In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.  

    Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation:  difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in Santarus' prior press releases as well as in public periodic filings with the Securities and Exchange Commission.

    You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Santarus® and ULTESA™ are trademarks of Santarus, Inc. GLUMETZA® is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. CYCLOSET® is a trademark of VeroScience LLC. MMX® is a trademark of Cosmo Technologies Limited. RHUCIN® is a trademark of Pharming Group NV.


    SOURCE Santarus, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results
    2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
    3. Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast
    4. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
    5. BD Announces Webcast of Annual Meeting of Shareholders
    6. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
    7. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
    8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
    9. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
    10. Cepheid to Webcast Upcoming Financial Presentation
    11. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
    Post Your Comments:
    (Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
    (Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
    (Date:12/1/2015)... , Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), ... commercialization of therapies for cardiovascular conditions via the inhalation ... business in Australia . InCarda is ... Australia in the first half ... and medical centers in Adelaide ...
    Breaking Medicine Technology:
    (Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy ... and funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving ... things from patients including their ability to work and be productive, to do simple ...
    (Date:12/1/2015)... ... 2015 , ... Henderson, a town of about 6,300 people, ... a partnership this year with Aeneas Internet and Telephone. , With faster Internet ... entrepreneurs who want to build a business. Whether startups or long established companies, ...
    (Date:12/1/2015)... ... ... Integrated Rental Services (“Integrated Rental”), a growing medical equipment ... With support from JII, Integrated Rental is poised for expansion while improving its ... labs and medical facilities across the United States. , General Manager Robert Bean ...
    (Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
    (Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
    Breaking Medicine News(10 mins):